Business
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China Initiated first-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 being developed for acne in the U.S. Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026 SAN MATEO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sagimet Bios
About this update from Sagimet Biosciences Inc. - Series A
[{"type":"image","alt":"Sagimet Biosciences Inc.","displaySize":"","headline":null,"caption":"Sagimet Biosciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/3e3b89356ea0d21f59c381949bb6af25"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AmJDa7oTdvowtNmgiL7OTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3e3b89356ea0d21f59c381949bb6af25","width":300,"height":110}},"lazy":false},{"type":"text","content":"Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China","length":151,"tagName":"p"},{"type":"text","content":"Initiated first-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 being developed for acne in the U.S.","length":116,"tagName":"p"},{"type":"text","content":"Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026","length":175,"tagName":"p"},{"type":"text","content":"SAN MATEO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended June 30, 2025, and provided recent corporate updates.","length":332,"tagName":"p"},{"type":"text","content":"“We are making strong progress advancing our differentiated therapeutics, which are in development for the treatment of MASH and acne,” said David Happel, Chief Executive Officer of Sagimet. “Following our license partner Ascletis’ announcement that denifanstat met all primary and secondary endpoints in its Phase 3 clinical trial in moderate to severe acne in China, in June, we initiated a Phase 1 clinical trial of our second FASN inhibitor, TVB-3567, for development of an acne indication. Additionally, pending consultation with regulatory authorities, we plan to initiate a Phase 1 clinical trial to evaluate the PK and tolerability of a combination of our FASN inhibitor denifanstat and resmetirom in the second half of 2025 as the first step towards development of a combination product for patients living with MASH. We co...